Skip to content
TrialScanner

NCT00349934

IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma

Phase 1CompletedIMMPLead

Registry record

Lead sponsor
Immutep S.A.S.
Conditions
Metastatic Breast Cancer
Primary completion
Nov 2009Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT00349934 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT00349934: IMP321 Plus First-line... | TrialScanner